Watchdog Calls On FDA To Set Policy For Use Of Unauthorized Tests In Public Health Emergencies
Executive Summary
The US Government Accountability Office reviewed how the FDA reviewed and monitored COVID-19 tests during the pandemic and found room for improvement. One particular concern was the lack of a straightforward policy on when enforcement discretion would be used.
You may also be interested in...
FDA Issues New COVID-19 EUA Requirements After HHS Restores Agency’s LDT Oversight Role
A controversial Trump-era policy that blocked the US FDA from regulating laboratory-developed tests was binned by the Health and Human Services secretary on 15 November. As a result, the FDA will once again require emergency use authorizations or other clearances for new COVID-19 tests.
FDA Cautions EUA-Holders They Have Same MDR Reporting Responsibilities As Other Manufacturers
In further sign the agency is tightening oversight of EUA products, regulators have set up a Q&A web page for manufacturers explaining their responsibilities to report adverse events.
COVID-19: FDA Eases Approval Policy By Allowing LDT Use Under ‘Immediately In Effect’ Guidance
The US FDA on 29 February issued a new guidance giving the OK to labs with pending COVID-19 laboratory-developed tests (LDTs) to use them while they await the agency’s approval under Emergency Use Authorization. The agency issued the guidance quickly, taking the unusual step of forgoing a public comment period.